NCT00137449 - Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG

SU011248

37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.

Trial Locations (4)

20133

Pfizer Investigational Site, Milan

69373

Pfizer Investigational Site, Lyon

94805

Pfizer Investigational Site, Villejuif

02115

Pfizer Investigational Site, Boston